Valentina Boni, MD, PhD, on Breast Cancer Advances from 2022 ASCO

CancerNetwork® spoke with Valentina Boni, MD, PhD, of the Early Drug Development Unit at the Universitary Hospital Universitario Quirónsalud Madrid as well as director and principal investigator at NEXT Oncology Madrid in Spain, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting about top trials in breast cancer.

Transcript:

2022 ASCO was a very interesting meeting, as always. The most important thing is that we had an opportunity to meet with other collaborative persons after more than 2 years. There are several other trials that are very interesting. The [phase 3] TROPiCS-02 [NCT03901339] with sacituzumab govitecan [Trodelvy] in patients with breast cancer that is hormone receptor–positive is a very important new trial, especially because it is a new antibody-drug conjugate that was previously approved in triple-negative breast cancer. It is going to be another standard of [care] therapy in hormone receptor–positive breast cancer.^1,2

In the plenary session, the results of [phase 3] DESTINY-Breast04 trial [NCT03734029] were presented.³ The activity of trastuzumab deruxtecan [Enhertu] in patients with hormone receptor–positive/HER2-low breast cancer. That is going to be a new standard of care for these patients. We have a lot of new and interesting data, and some of them are going to change the clinical practice in metastatic breast cancer.

References

1. Rugo HS, Bardia A, Marme F, et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. J Clin Oncol. 2022;40(suppl 17):LBA1001-LBA1001. doi: 10.1200/JCO.2022.40.17_suppl.LBA1001
2. FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer. News Release. FDA. April 7, 2021. Accessed July 8, 2022. https://bit.ly/3yN1Vzz
3. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9-20. doi:10.1056/NEJMoa2203690